Consistent with the results of the TCGA database, higher mRNA DPYSL2 expression levels were also found in AML‐M5 patients in our cohort (Figure S2C‐D), and patients with high DPYSL2 expression had a shorter OS (p = 0.001) (Figure 2E) and a worse EFS (p = 0.003) (Figure 2F) and RFS (p = 0.015) (Figure 2G). This evidence concerns the gene DPYSL2 and acute myeloid leukemia.